Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 3/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | CTSE | P14091 | 1/20 | 0.47 |
| ▸ | PGC | P20142 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498118 | 0.87 | REN (0.56) | CTSSCTSKREN | |
| SCHEMBL29112224 | 0.87 | MME (0.58) | BACE1 | |
| SCHEMBL7270319 | 0.85 | CTSS (0.52) | CTSSCTSKCTSDCTSEPGC | |
| SCHEMBL24346073 | 0.84 | CTSS (0.57) | CTSSCTSKBACE1CTSDCTSE | |
| SCHEMBL7419119 | 0.80 | CPA1 (0.53) | CTSKBACE1BACE2CTSD | |
| SCHEMBL23572631 | 0.80 | ACE (0.55) | CTSSCTSKBACE1BACE2CASP1 | |
| SCHEMBL23572632 | 0.80 | ACE (0.55) | CTSSCTSKBACE1BACE2CASP1 | |
| SCHEMBL23600925 | 0.80 | ACE (0.55) | CTSSCTSKBACE1BACE2CASP1 | |
| SCHEMBL14274753 | 0.79 | OPRM1 (0.56) | CTSSCTSK | |
| SCHEMBL7421185 | 0.79 | CPA1 (0.59) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3995486-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | AGC INC. (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20220119440-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | AGC Inc. (JP) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119440-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | VIP, RFC2, QRFPR | CTSS 786/4885CTSK 910/4885BACE1 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.